Abbott Laboratories $ABT Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its holdings in Abbott Laboratories (NYSE:ABT) by 86.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 253,593 shares of the healthcare product maker’s stock after selling 1,655,621 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Abbott Laboratories were worth $33,966,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC grew its stake in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Tradition Wealth Management LLC lifted its holdings in shares of Abbott Laboratories by 1.5% during the first quarter. Tradition Wealth Management LLC now owns 6,388 shares of the healthcare product maker’s stock worth $847,000 after purchasing an additional 92 shares during the period. TFB Advisors LLC grew its position in Abbott Laboratories by 6.2% in the 1st quarter. TFB Advisors LLC now owns 3,207 shares of the healthcare product maker’s stock valued at $425,000 after buying an additional 188 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Abbott Laboratories by 9.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,170,523 shares of the healthcare product maker’s stock valued at $553,220,000 after buying an additional 375,168 shares during the period. Finally, Summit Financial LLC raised its position in Abbott Laboratories by 11.7% during the 1st quarter. Summit Financial LLC now owns 65,838 shares of the healthcare product maker’s stock worth $8,733,000 after buying an additional 6,899 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 1.3%

Abbott Laboratories stock opened at $125.01 on Friday. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The firm has a market capitalization of $217.37 billion, a price-to-earnings ratio of 15.67, a price-to-earnings-growth ratio of 2.31 and a beta of 0.72. The stock’s fifty day moving average is $126.91 and its two-hundred day moving average is $130.32. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, hitting the consensus estimate of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The business had revenue of $11.37 billion for the quarter, compared to analyst estimates of $11.40 billion. During the same period in the previous year, the firm earned $1.21 EPS. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be paid a dividend of $0.63 per share. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.0%. Abbott Laboratories’s dividend payout ratio is 29.57%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Evercore ISI dropped their price target on shares of Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 15th. The Goldman Sachs Group boosted their target price on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Royal Bank Of Canada reissued an “outperform” rating and issued a $147.00 price target on shares of Abbott Laboratories in a report on Thursday, October 16th. Raymond James Financial increased their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Finally, BTIG Research restated a “buy” rating and set a $145.00 target price on shares of Abbott Laboratories in a research report on Thursday, November 20th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $147.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.